-
Study aim
-
Determination of the effect of hydrocortisone on hemodynamic changes including arterial blood pressure and heart rate resulting from the neuromuscular relaxant atracurium
-
Design
-
A clinical trial with the control group, with parallel groups, double-blind, randomized, phase 3 on 48 patients. G * Power software was used for randomization.
-
Settings and conduct
-
The present study will be a double-blind randomized clinical trial (patient and outcome assessor) performed on individuals aged 15 to 60 years to determine the effects of hydrocortisone on hemodynamic changes induced by atracurium for intubation in patients under general anesthesia referred to 5 Azarshahr Medical Center. Gorgan will be done in 2022.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: All patients for elective upper limb fracture surgery between the ages of 15-60 with ASA I or II, Exclusion criteria: neuromuscular disorders, receiving antibiotics including aminoglycosides 24 hours before surgery, liver disease And kidney, diabetes, heart failure, allergy to corticosteroids, obesity, taking H1 histamine blocker one day before surgery, lactating and pregnant mothers, psychotic disorders,hypothyroidism,Osteoporosis
-
Intervention groups
-
Intervention group: 100 mg Jaber hydrocortisone vial with the generic name: Hydrocortisone-Systemic (manufacturer of Jaber Bin Hayan Pharmacy [Iran]) once, 30 minutes before entering the operating room (in the ward) intravenously and bolus with 300 ml They receive normal saline under the supervision of a nurse who has no knowledge of the study groups.
Control group: Individuals in the placebo group received the same amount of distilled water with 300 ml of normal saline under the supervision of a nurse who is unaware of the drug groups.
-
Main outcome variables
-
Hemodynamic changes
Bronchospasm
Number of breaths